# US 5,352,583 A · Human tissue plasminogen activator-human plasminogen activator inhibitor complex immunoassay and kit therefor > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 5,352,583 A - Document ID: US5352583A - Status: Granted - Kind: A - Application number: 07/687,867 - Filed: 1991-06-03 - Granted: 1994-10-04 - Earliest claimed: 1989-10-02 - Assignees: Teijin Limited - Inventors: Yoichi Sakata; Kazuhiko Itoh; Shuichiro Hino; Ryoichi Hasegawa; Naomi Okamoto; Atsushi Noro; Toshinobu Murakami - Web page: https://patentgrep.com/patent/US5352583A ## CPC - G01N 33/54393: {Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding} - G01N 33/54306: {Solid-phase reaction mechanisms} - G01N 33/86: involving blood coagulating time {or factors, or their receptors} - G01N 2333/8132: Plasminogen activator inhibitors - G01N 2333/9726: Tissue plasminogen activator - Y10S 435/962: Prevention or removal of interfering materials or reactants or other treatment to enhance results, e.g. determining or preventing nonspecific binding - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) - Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS ## Abstract A kit for the immunological assay of the human tissue plasminogen activator-human plasminogen activator inhibitor complex in a human specimen, which kit comprises (i) a monoclonal antibody (first antibody) against a human plasminogen activator inhibitor linked onto an insoluble solid carrier having a specular surface, (ii) a polyclonal antibody (second antibody) against a human tissue plasminogen activator labelled by an enzyme, (iii) a substrate and a reaction-discontinuing agent for the assay of the enzyme activity, (iv) a diluent, and (v) a detergent containing a nonionic surfactant having an HLB (Hydrophile Lipophile Balance) value of at least 16, and a method for the immunological assay of the above complex and a method for the immunological assay of the active human plasminogen activator inhibitor, respectively in a human specimen using this kit. ## Claims ### Claim 1 A method for an immunological assay of a human tissue plasminogen activator-human plasminogen activator inhibitor complex in a human specimen by: (1) contacting the human specimen with a first antibody linked to an insoluble solid carrier, and then contacting a labeled second antibody therewith, or (2) simultaneously contacting a first antibody linked to an insoluble solid carrier and a labeled second antibody with the human specimen, steps (1) and (2) being performed in the presence of a surfactant, (3) and, following step (1) or (2), measuring said labeled second antibody bound to said solid carrier to determine the human tissue plasminogen activator-human plasminogen activator inhibitor complex in the human specimen, which method comprises: (a) using as the first antibody a monoclonal antibody which specifically binds a human plasminogen activator inhibitor JTI-4 produced by the hybridoma JTI-4 (FERM BP-2318) linked onto an insoluble solid carrier having a specular surface, (b) using as the second antibody a polyclonal antibody which specifically binds a human tissue plasminogen activator labeled with an enzyme, and (c) said surfactant being a nonionic surfactant having an HLB (Hydrophilic-Lipophilic Balance) value of at least 16 and a concentration of 0.001-0.1 w/w %, said nonionic surfactant being at least one member selected from the group consisting of polyoxyalkylene alkyl aryl ether series, polyoxyalkylene alkyl ether series, polyoxyalkylene polyhydric alcohol fatty acid ester series and polyoxyethylene polyoxypropylene polyol series. ### Claim 2 (depends on 1) The method for the immunological assay of claim 1 which comprises contacting the human specimen with the first antibody linked to the insoluble solid carrier, and then contacting with the labeled second antibody. ### Claim 3 (depends on 1, 2) The method for the immunological assay of claim 1 or 2 wherein a nonspecific adsorption inhibiting protein having a molecular weight of about 16,000 to about 50,000 and an isoelectric point of 1.0 to 5.0 contained in the second antibody and/or a diluent is further contacted such that the final concentration of said protein in the immune reaction solution is adjusted to 0.02-0.9% by weight. ### Claim 4 (depends on 1, 2) The method for the immunological assay of claim 1 or 2 wherein the insoluble solid carrier is a polystyrene bead having a specular surface. ### Claim 5 (depends on 3) The method for the immunological assay of claim 3 wherein the protein is casein. ### Claim 6 An immunological assay for active human plasminogen activator inhibitor which comprises: (1) providing two aliquots of a human specimen containing (i) a human tissue plasminogen activator-human plasminogen activator inhibitor complex and (ii) active human plasminogen activator inhibitor, (2) adding a sufficient amount of free human tissue plasminogen activator to one of the two aliquots to complex the active human plasminogen activator inhibitor, (3) contacting both the aliquots individually with a first antibody linked to an insoluble solid carrier, and then contacting a labeled second antibody therewith, or (4) simultaneously contacting the first antibody linked to the insoluble solid carrier and the labeled second antibody with the aliquots individually, steps (3) and (4) being performed in the presence of a surfactant, (5) measuring solid phase bound label to determine the amount of human plasminogen activator-human tissue plasminogen activator inhibitor complex in each of the aliquots, and (6) determining the amount of active human plasminogen activator inhibitor based on the difference between the amount of human tissue plasminogen activator-human plasminogen activator inhibitor complex in the two aliquots, and wherein (a) there is used as the first antibody a monoclonal antibody JTI-4 produced by the hybridoma JTI-4 (FERM BP-2318) which specifically binds a human plasminogen activator inhibitor linked to an insoluble solid carrier having a specular surface, (b) there is used as the second antibody a polyclonal antibody which specifically binds a human tissue plasminogen activator labeled with an enzyme, and (c) there is used as the surfactant a nonionic surfactant having an HLB (Hydrophilic-Lipophilic Balance) of at least 16 and a concentration of 0.001-0.1 w/w %, said nonionic surfactant being at least one member selected from the group consisting of polyoxyalkylene alkyl aryl ether series, polyoxyalkylene alkyl ether series, polyoxyalkylene polyhydric alcohol fatty acid ester series and polyoxyethylene polyoxypropylene polyol series.